Who are Yangxinshi tablet simulants's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Twice Normal-dose Wenxin Granules, Jinlida granules, DING KUN DAN, Songling Xuemaikang Capsules, Compound Ciwujia Granules, Louxiangdan Tongxin granules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/yangxinshi-tablet-simulants.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Yangxinshi tablet simulants — Competitive Intelligence Brief

Yangxinshi tablet simulants (Yangxinshi tablet simulants) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine herbal formulation. Area: Cardiovascular.

marketed Traditional Chinese medicine herbal formulation Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Yangxinshi tablet simulants (Yangxinshi tablet simulants) — Dongzhimen Hospital, Beijing. Yangxinshi tablet is a traditional Chinese medicine formulation that supports cardiac function and improves blood circulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Yangxinshi tablet simulants TARGET	Yangxinshi tablet simulants	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine herbal formulation
Twice Normal-dose Wenxin Granules	Twice Normal-dose Wenxin Granules	China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine herbal formulation
Jinlida granules	Jinlida granules	Shanghai Jiao Tong University School of Medicine	marketed	Traditional Chinese medicine herbal formulation
DING KUN DAN	DING KUN DAN	Peking Union Medical College Hospital	marketed	Traditional Chinese medicine herbal formulation
Songling Xuemaikang Capsules	Songling Xuemaikang Capsules	Xiyuan Hospital of China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine herbal formulation
Compound Ciwujia Granules	Compound Ciwujia Granules	Shanghai Municipal Hospital of Traditional Chinese Medicine	marketed	Traditional Chinese medicine herbal formulation
Louxiangdan Tongxin granules	Louxiangdan Tongxin granules	Liaoning University of Traditional Chinese Medicine	marketed	Traditional Chinese medicine herbal formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine herbal formulation class)

Beijing Bozhiyin T&S Co., Ltd. · 1 drug in this class
China Academy of Chinese Medical Sciences · 1 drug in this class
Dongzhimen Hospital, Beijing · 1 drug in this class
Jinling Hospital, China · 1 drug in this class
Liaoning University of Traditional Chinese Medicine · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Qilu Hospital of Shandong University · 1 drug in this class
Shanghai Institute of Hypertension · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Shanghai Municipal Hospital of Traditional Chinese Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Yangxinshi tablet simulants — Competitive Intelligence Brief. https://druglandscape.com/ci/yangxinshi-tablet-simulants. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab